International Corporate Finance

INTERNATIONAL CORPORATE FINANCE 50 LEADERS

IPO LEADERS

Has been the CEO of BeiGene since its beginnings in 2010

Aims to develop a new generation of immuno-oncology drugs for cancer treatment

Despite John Oyler’s engineering background, life sciences have

always been his passion. This is why he founded and served as

CEO for a number of companies in this field. He was behind some

of the top US pharma companies: Genta, Galenea and BioDuro.

John Oyler has made it clear that above all he seeks to guide a com-

pany that has meaning and is impactful. His international experiences

have led him to work with leading experts from around the world.

BeiGene, his newest prized possession, is geared towards crea-

ting the next generation of cancer treatment. As the second com-

pany to proceed with IPO in the United States in 2016, it had

remarkable success on the Nasdaq raising around $158.4 million

dollars which is more than what was initially expected.

Bei Gene currently has 215 employees and consultants that work

at the company’s headquarters in China, the US and Australia.

John Oyler

CEO, BEIGENE

A seasoned pharma sector leader with 25 years experience in corporate strategy and M&A

Lead one of the most successful and unique genetic disease treatment focused IPOs of 2016

President and CEO of AveXis, one of the most successful IPO sto-

ries of 2016 with an increase in share price of over 100% since

listing, Sean Nolan is a pharma industry veteran who successfully

created value for many publicly held as well as private companies.

At AveXis, Sean is relentlessly focused on commercializing treat-

ments for rare and life-threatening neurological genetic diseases.

Sean started his career with Abbott as a Sales Rep in 1991, and

rose to the rank of Senior Director by 2003. He also held C-level

roles at Lundbeck Inc., Reata Pharmaceuticals and Intermune –

where he led their North American operations and helped launch

Pirfenidone (a treatment for a devastating orphan disease).

In addition to his broad-base experience at a large multi-national

such as Abbott, Mr. Nolan has also had exposure to M&A activities

in both a private equity backed company and a public biotech firm.

Sean P. Nolan

President and CEO, AVEXIS © BeiGene